

The conscious sedation is a fast and safe option to perform intracavitary brachytherapy in carcinoma cervix patients: An institutional experience

Narendra Rathore^{1,*}, Lalit Raigar², Arvind K. Shukla³, Abhay K. Jain⁴, Vikram Raj Purohit⁵

¹Assistant Professor, ^{4,5}Junior Resident, Dept. of Radiotherapy & Oncology, ²Senior Professor, Dept. of Anaesthesiology, ³Assistant Professor, Radiological Physics, Dept. of Radiotherapy, RNT Medical College, Udaipur, Rajasthan

***Corresponding Author:**

Email: drnarendra_rathore@yahoo.com

Abstract

Purpose: To know the complications of conscious sedation in cervical cancer patients treated with cobalt (CO60) based Intracavitary brachytherapy (ICRT) and to assess pain on visual analogue scale (VAS).

Materials and Method: Cobalt intracavitary brachytherapy application was performed with conscious sedation in 40 carcinoma cervix patients and post-procedural pain was assessed with VAS at every 30 minutes interval for six hours along with other complications.

Result: Pain was well controlled (mean VAS 4.5) in all patients with maximum VAS 10 and tramadol was received as rescue analgesic. Common complication was grade 1 & 2 bradycardia in 8 patients; and grade 1 hypertension in 6 applications; no patients found Gr 3 or 4 hypertension, Hypotension in 11 Patients (Gr1 in 7).

Conclusions: Conscious sedation is a fast and safe option to perform intracavitary brachytherapy applications (Cobalt 60) in the patients of cervix cancer.

Keywords: Intracavitary Brachytherapy, Conscious Sedation, Cervix Cancer

Received: 22nd December, 2016

Accepted: 8th March, 2017

Purpose

India accounts for one fifth of the global burden of cervical cancer and this is the second most common malignancy among females.⁽¹⁾

The concurrent external beam radiotherapy (EBRT) followed by intracavitary radiotherapy (ICRT) is proved as the main treatment therapy.⁽²⁻⁵⁾

ICRT plays very important role in the management of gynecological cancers.⁽⁶⁾ It is a means to deliver the required dose of brachytherapy to cervix and parametrium with relative sparing of the adjoining normal structure.⁽⁷⁾

According to American brachytherapy society guidelines,⁽⁸⁾ brachytherapy should be done under general anesthesia (GA) as it provides good analgesia and muscle relaxation but it has shown to be associated with higher complications (hypotension, bradycardia etc.).⁽⁹⁾ To facilitate this procedure under GA is very time consuming specially in such Institute having heavy patients load or less manpower. Sometimes it is very difficult to manage complications too of GA as well as co-existing disease itself and as per protocol these patients have to undergo pre-anaesthetic examination and clearance.

On the other side, ICRT in conscious sedation is simple and convenient to practice, not requiring pre-anesthetic clearance but may cause pain, discomfort and poor muscle relaxation, which may lead to compromising dosimetry.⁽¹⁰⁾

Our center is one of the centers in India where new registration of patients suffering with cervix cancer is

very high (average 1000 patients/ year with age of 30-60 years).

So the aim of this study is to assess pain, sedation and other complication with conscious sedation and easiness of ICRT application in cervical cancer patients treated with CO⁶⁰ based ICRT.

Materials and Method

This study was conducted prospectively on 40 patients of cervical cancer with stage IB₂ to IIIB posted for ICRT application. The Definitive & conventional EBRT was prescribed with dose 45-50 Gy in 25 fractions by Cobalt 60 teletherapy machine. ICRT was started after 1 week of EBRT completion. Total four sessions of ICRT @ 6 Gy /session was delivered maintaining of a gap of 72 hours between two sessions.

The all procedures were done in lithotomy position. Fletcher suit type of applicators was used and dose delivery equipment was HDR remote after loading brachytherapy unit. After placement of Fletcher suite applicator, the orthogonal view was reconstructed and treatment planning was done on treatment planning system. Dose prescription was specified to point "A". Multiple points consistent with ICRU 38 were located and used for treatment planning and dose optimization to point A, bladder and rectum.⁽¹¹⁾

Patient kept overnight fasting before bringing in OT and vitals was noted and pre-medicated with inj. Ondansetron 4mg i.v. and inj. Diclofenac 75mg i.v. slow 30minutes before procedure and then Inj. Midazolam 0.5-8 mg (median 2.5mg) slow i.v. infusion.

Post procedure pain in moderate conscious sedation was assessed using VAS every 30 minutes for 6 hrs and sedation as described by American society of anaesthesiologists⁽¹²⁾ **Visual Analogue Scale.**⁽¹³⁾

Pain intensity	Word scale
0	No pain
1-2	Least pain
3-4	Mild pain
5-6	Moderate pain
7-8	Severe pain
9-10	Excruciating pain

When pain score >3 supplementary, Inj. Tramadol 2mg/kg intravenous was given as rescue analgesic and if there is more severe pain inj fentanyl 1-2µg/kg was supplemented.

Complications were recorded regularly up to 6 hours of the applications and grading of complication was done according to the common terminology criteria for adverse events (CTCAE) 4.03 guideline.⁽¹⁴⁾

Results

Patient characteristics: Most patients belonged to stage II. (Table 1)

Total 6 parameters were analyzed i.e., Dose to point A₁, Dose to point A₂, Bladder max dose(B_{max}), Rectal max dose(R_{max}), maximum VAS score and grades of complications.

Max VAS score in conscious sedation: Most common Maximum VAS score was 5 in 10 applications while second most score was 4 in 8 applications. The mean of maximum pain score was 4.55 and similarly the median was 4.5. (Table 4 & Fig. 3). In two procedures mild to moderate pain was managed by inj Tramadol 2mg/kg while more (VAS>7) was managed by inj Fentanyl (50 µg increment)

Complications with grade: Most common complication was grade1 and grade 2 bradycardia (in 8 out of 40 applications), hypertension (grade 1 in 6 applications), Hypotension (gr 1 in 7 and Gr 2 in 4 patients) was manageable with fluid administration and ventricular dysrhythmia (grade 1 in 3 applications) (Table V). All were transient not required any medication except one patient required inj atropine 0.6mg).

Dose to point A: The Dose range of Point A was from 5.5 to 6.5 Gy in majorities of applications (90%, 36 out of 40). The average doses were 5.92Gy and 5.97 Gy for Point A1 and A2 respectively. (Table 2 & Fig. 1)




Fig. 1: Showing target dose range (Gy) and no of applications

Bladder max and rectal max dose distribution: The Bladder max ranges from 21.2-111% (1.27-6.66 Gy). Similarly, the rectal max ranges from 1.53-5.45Gy (25.5-90%). (Table 3 & Fig. 2)

Table 1: Showing patient characteristics

Sr. No.	Attributes	
1.	Median age (years)	45
2.	FIGO stage (no. Of patients)	
	I	3
	II	6
	III	1
3.	Median EBRT dose (Gy)	50
4.	Median duration of treatment (days)	60
5.	ICRT	30
	Average applicator insertion time in OT (minutes)	6
	Dose per fraction (Gy)	5
	Median length of uterine cavity (cm)	Medium
	Median ovoid size	

Table 2: Showing target Point A dose distribution

Target dose range (Gy)	Distribution at Point A1	Distribution at Point A2
4.5-5	2	0
5-5.5	9	10
5.5-6	14	18
6-6.5	13	8
6.5-7	2	4

Table 3: Showing bladder max dose Distribution

Dose range (% to dose received at point A)	Bladder	Rectum
	max	max
21-40	10	6
41-60	13	14
61-80	11	14
81-100	5	6
101-120	1	0

Table 4: Showing max pain score recorded up to 6 hours

No. of procedures	Max VAS score
2	0
2	1
4	2
4	3
8	4
10	5
2	6
2	7
4	8
0	9
2	10

Table 5: Showing maximum grade of complications recorded up to 6 hours

Complication	Grade				
	1	2	3	4	5
Hypotension	7	4	0	0	0
Bradycardia	5	3	0	0	0
Hypertension	6	0	0	0	0
Ventricular dysrhythmia	3	0	0	0	0
Laryngo spasm	0	0	0	0	0




Fig. 2: Showing Bmax dose range (% of dose received at point A) on X-axis and no of application on Y-axis




Fig. 3: Showing distribution of max pain score in different procedures



Fig. 4: Dose distribution in AP and Lat Radiograph




Fig. 5: Dose distribution in X, Y and Z plane

Discussion

Total 40 ICRT applications were performed and the dose of 6 Gy was prescribed to target point A in each application. Overall dosimetric dose distribution was well and satisfactory. (Fig. 4 and 5)

The max bladder dose was ranges from 21.2 to 111% (1.27-6.66 Gy) of the dose prescribed to point A. While the max rectum dose were ranges between 25.5 to 90% (1.53-5.45Gy).

In Bhanabhai et al study,⁽¹⁵⁾ 57 procedures of ICRT were done with conscious sedation. The mean and median pain scores during the procedures were 1.4 and 1.1 respectively. Brief moments of moderate to severe incidental pain were noted at the time of certain events

during procedure-specifically during insertion and removal of ovoids and tandem applicator. The maximum pain score during entire procedure ranged from 0 to 10 (median: 4.7). No significant cardiovascular events were noted.

In our study, the mean and median pain scores during the procedures were 1.3 and 1 respectively. Maximum pain was noted at the time of insertion and removal of ovoid and tandem applicator similar to Bhanabhai et al.⁽¹⁵⁾ There pain was managed by inj. Tramadol 2mg/kg wt and in only two patients it was supplemented with inj. Fentanyl 100µg and after the procedure was completed.

The cardiovascular complication –hypotension, bradycardia were transient and not required any management

Conclusion

Conscious sedation is a fast and safe option to perform intracavitary brachytherapy in carcinoma cervix patients at higher workload department. It has good pain control and lack of fatal cardiovascular adverse events and without compromising dosimetric distribution. With this technique it will reduce workload of post-operative ward as well as.

References

1. Mallath MK, Taylor DG, Badwe RA et al. The growing burden of cancer in India: epidemiology and social context. *Lancet Oncol* 2014;15:205–12.
2. Landoni F, Maneo A, Colombo A et al. Randomised study of radical surgery v/s radiotherapy for Ib- Iia cervical cancer. *Lancet* 1997;350:535-40.
3. Fletcher GH, Shukovsky LJ. The interplay of radiocurability and tolerance in the irradiation of human cancers. *J Radiol Electrol Med Nucl* 1975;56:383-400.
4. Ntekim A, Adenipekun A, Akinlade B et al. High Dose Rate Brachytherapy in the Treatment of cervical cancer: preliminary experience with cobalt 60 Radionuclide source: A Prospective Study. *Clin Med Insights Oncol* 2010;4:89–94.
5. Au-Yeung G, Mileskin L, Bernshaw DM et al. Radiation with cisplatin for locally advanced cervix cancer: The experience of a tertiary cancer centre. *J Med Imaging Radiat Oncol* 2013;57:97-104.
6. Eifel P. Patterns of radiotherapy practice for patients treated for intact cervical cancer in 2005-2007: a Quality Research in Radiation Oncology (QRRO) study. *Int J Radiat Biol Phys* 2010;78:S119.
7. Vale C, Tierney JF, Stewart LA et al. Chemotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. *J Clin Oncol* 2008;26:5802–12.
8. Viswanathan AN, Thomadsen B. American brachytherapy society consensus guidelines for carcinoma cervix. *Brachytherapy* 2012;11:33-46.
9. Benrath J, Langenecker SK, Hupfl M et al. Anaesthesia for brachytherapy-5½ yrs of experience in 1622 procedures. *Br j anaesth* 2006;96:195-200.
10. Lim KH, Lu JJ, Wynne CJ et al. A study of complications arising from different methods of anaesthesia used in

HDR brachytherapy for cervical cancer. *Am J Clin Oncol* 2004;27:449-51.

11. Dose and Volume Specification for Reporting Intracavitary Therapy in Gynecology. (International Commission on Radiation Units & Measurements, Report No.38;1985).
12. American Society of Anesthesiologists task force on sedation and analgesia by non-anesthesiologists. Practice guidelines for non-anesthesiologists. *Anesthesiology* 2002;96:1004-17.
13. Ducharme J. Proceedings from the First International Symposium on Pain Research in Emergency Medicine: Foreword. *Ann Emerg Med*. 1996;27:399–403.
14. Common Terminology Criteria for Adverse Events. Department of Health and Human Services, National Institutes of Health, National Cancer Institute: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.0_3_2010-06-14_QuickReference_5x7.pdf.
15. Bhanabhai H, Samant R, E C, Grenier L et al. Pain assessment during conscious sedation for cervical cancer HDR brachytherapy. *Curr Oncol* 2013;20:e307-10.